Literature DB >> 8445821

Understanding consequences of concurrent therapies.

C C Peck, R Temple, J M Collins.   

Abstract

Mesh：

Substances：

Year:  1993        PMID： 8445821

Source DB:  PubMed          Journal:  JAMA        ISSN： 0098-7484            Impact factor:   56.272


× No keyword cloud information.
  17 in total

1.  Drug-drug pharmacodynamic interaction detection by a nonparametric population approach. Influence of design and of interindividual variability.

Authors:  Y Merlé; A Mallet; E Schmautz
Journal:  J Pharmacokinet Biopharm       Date:  1999-10

Review 2.  Cytochrome P4503A (CYP3A) metabolism: prediction of in vivo activity in humans.

Authors:  G R Wilkinson
Journal:  J Pharmacokinet Biopharm       Date:  1996-10

Review 3.  Quantitative clinical pharmacology is transforming drug regulation.

Authors:  Carl C Peck
Journal:  J Pharmacokinet Pharmacodyn       Date:  2010-10-27       Impact factor: 2.745

4.  Mechanism of block of a human cardiac potassium channel by terfenadine racemate and enantiomers.

Authors:  T Yang; C Prakash; D M Roden; D J Snyders
Journal:  Br J Pharmacol       Date:  1995-05       Impact factor: 8.739

Review 5.  Inhibition and induction of cytochrome P450 and the clinical implications.

Authors:  J H Lin; A Y Lu
Journal:  Clin Pharmacokinet       Date:  1998-11       Impact factor: 6.447

6.  Identification of the major human liver cytochrome P450 isoform(s) responsible for the formation of the primary metabolites of ziprasidone and prediction of possible drug interactions.

Authors:  C Prakash; A Kamel; D Cui; R D Whalen; J J Miceli; D Tweedie
Journal:  Br J Clin Pharmacol       Date:  2000       Impact factor: 4.335

7.  Development of a generalized, quantitative physicochemical model of CYP3A4 inhibition for use in early drug discovery.

Authors:  R J Riley; A J Parker; S Trigg; C N Manners
Journal:  Pharm Res       Date:  2001-05       Impact factor: 4.200

8.  The effect of RPR 102341 on theophylline metabolism and phenacetin O-deethylase activity in human liver microsomes.

Authors:  R B White; H Heyn; J C Stevens
Journal:  Pharm Res       Date:  1997-04       Impact factor: 4.200

Review 9.  Polypharmacy. Pharmacokinetic perspectives.

Authors:  P K Honig; L R Cantilena
Journal:  Clin Pharmacokinet       Date:  1994-02       Impact factor: 6.447

Review 10.  Inhibition of terfenadine metabolism. Pharmacokinetic and pharmacodynamic consequences.

Authors:  K T Kivistö; P J Neuvonen; U Klotz
Journal:  Clin Pharmacokinet       Date:  1994-07       Impact factor: 6.447
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.